TOKYO, Mar 4, 2026 - (ACN Newswire via SeaPRwire.com) - JCB Co., Ltd. (JCB), together with Resona Holdings, Inc. (Resona; TSE: 8308), announced the start of a project to commercialize ultra-wideband (UWB) payments that realize a new purchasing experience using UWB communication.The two companies have agreed to launch the world's first full-scale project for the practical application and commercialization of UWB payments. In 2026, JCB will work with multiple technology partners and collaborating merchants to demonstrate payment technology and value-added solutions for merchants, as well as user experience building projects to create new purchasing experiences. On top of that, JCB aims to launch small-scale commercial operations in 2027 and full-scale commercialization in earnest in 2028.The two companies are participating in the FiRa® Consortium, which standardizes and contributes to the development of UWB communication technology, as well as builds new payment experiences and value-added solutions for stores using UWB technology.About the UWB Payment ProjectThrough the activities of the FiRa Consortium, JCB, and Resona will standardize technologies and experiences for payment applications, and with the support of FiRa Consortium’s participating vendors, conduct technology tests. From 2026, the two companies will demonstrate UWB payments and value-added solutions together with multiple partner merchants and provide feedback to FiRa on the necessary technology development.In parallel, JCB and Resona will conduct research on user experience and store payment operations to confirm user and merchant acceptability.Moreover, to reduce the introduction load for merchants as much as possible, the project aims to build a payment infrastructure that can widely accept payment solutions using UWB from competitors. The project is aimed to launch on a small scale in 2027 and commercialize on a full-scale in 2028.In addition, the two companies will aim to realize new UWB payments through collaboration with a wide range of partners in Japan and other countries.Image of UWB paymentThe Background of This ProjectUWB communication technology is a short-range wireless communication technology that has the characteristics of (1) accurate location of devices and (2) high-speed data communication and is being used in Japan and overseas for location verification of digital keys for cars and homes, indoor navigation, and tags.The technology is also used overseas in gateless public transportation systems. In the future, it is expected to be used for payments, as with NFC (Near Field Communication) and QR codes.Outside Japan, the spread of smartphones with UWB functions has been slow, but in Japan, smartphones that can use UWB communication are widely available, and can be utilized in advance of the rest of the world. Moreover, the diversification of cashless payments and the wide range of value-added solutions for users and stores are also characteristics of Japan's payment scene. The project believes that it is necessary to take advantage of this location and create new payment solutions to solve problems for users and stores and meet the needs of new solutions.Overview of “UWB Payments”UWB payments can greatly improve the purchasing experience. Until now, it has been necessary to physically touch a card or smartphone at a payment terminal in a merchant or to scan a QR code. UWB payments will leverage short-range communication characteristics to create a new purchasing experience, such as hands-free payments even with a smartphone in a pocket or bag, and to instantly convey user information, such as diet restrictions, to merchants.Also, by utilizing the accurate location information of smartphones, it is possible to realize value-added solutions for both users and merchants that have never been seen before, such as improving the efficiency of navigation and waiting in stores, distributing personalized advertisements and coupons using smart displays, and providing new customer service for VIP customers. It is expected to be used not only to improve the experience but also to be used as a labor-saving solution to address labor shortages.Comparison of NFC and UWB paymentsExamples of value-added solutions:Provide communication functions for both users and merchants. For example, it can be used to automate the communication of requests such as food allergy information, whether or not plastic bags are needed, whether receipts are present and addressed, loyalty program information, whether coupons are available and used, and requests such as handicap and assistance needs, and children's chair preparations.Provide special customer service experiences for VIP customers and support store operations. Customers can receive a special customer service experience without verbally communicating with the merchant’s staff, allowing stores to provide appropriate customer service based on specific customer needs.Enable 1-to-1 marketing capabilities for customers. Marketing utilization, such as displaying personalized information on smart displays near customers, distributing coupons to customers, and displaying personalized pricing.Past UWB Payments InitiativesIn January 2024, JCB and Resona entered into a strategic partnership for the "Hands-free Payment" project, an initiative to build a new payment experience that does not require smartphone operation using device-to-device communication technology. Using UWB communication technology by linking the smartphones held by customers who visit the store with payment terminals and various IoT devices installed in the store, it allows customers to complete the payment process from authentication to payment procedure without taking out a smartphone or activating the screen, and even keeping their smartphone in their bag or pocket. By utilizing this solution, customers can grasp information at the time of their visit to the store and receive customer service and new in-store experiences, such as providing services for VIPs, preferential treatment, and coupon distribution.JCB also announced the development of a UWB-enabled app for iPhones and Apple Watches to support the project, along with a reference model of store checkout equipment and the launch of user testing. Through these efforts, JCB and Resona have been discussing and collaborating with their collaborative partners on technologies and business models.Looking ahead, JCB and Resona will work with multiple technology partners and collaborating merchants to carry out proof-of-concept initiatives for payment and merchant value-added solutions in 2026, with a phased commercial rollout planned for 2027 and full-scale commercialization targeted for 2028.About FiRa ConsortiumThe FiRa Consortium is a member-driven organization dedicated to transforming the way we interact with our environment by enabling precise location awareness for people and devices using the secured fine-ranging and positioning capabilities of Ultra-Wideband (UWB) technology. FiRa does this by driving the development of technical specifications and certifications, advocating for effective regulations, and defining a broad set of UWB use cases. To learn more about UWB and the FiRa Consortium, visit www.firaconsortium.org.About Resona Holdings, Inc.With the Group's purpose of "Making the future positive with finance +," we continue to take on the challenge of transformation and creation in order to transform the future into a positive one with ideas that go beyond the framework of finance. Adhering to our basic stance of "customer joy is Resona's joy," we will work to "strengthen value creativity" and "next-generation management infrastructure" to respond to customers and local communities.About JCB Co., Ltd.JCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 71 million merchants worldwide. JCB Cards are now issued mainly in Asian countries and territories, with more than 175 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solutions provider, JCB is committed to delivering responsive, high-quality products and services to all customers worldwide.For more information, please visit: www.global.jcb/en/ContactAnna TakedaJCB Corporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ANTWERPEN, BELGIUM, Mar 3, 2026 - (ACN Newswire via SeaPRwire.com) - OMP, a leading provider of AI-powered supply chain planning solutions, launches Unison Decision-Centric Planning, a new approach that helps organizations move from reactive, process-driven planning to proactive, event-driven decision-making.Built on OMP's flagship Unison Planning™ platform, Unison Decision-Centric Planning combines advanced AI, autonomous agents, real-time scenario modeling, and human validation to accelerate decision velocity. The approach enables organizations to anticipate disruption, evaluate trade-offs, and act with confidence in increasingly volatile supply chain environments.From reactive to proactive supply chain planningTraditional planning cycles are often too slow to keep pace with today's volatility. Unison Decision-Centric Planning replaces static, process-driven planning with a dynamic, decision-first approach that continuously senses change, identifies relevant scenarios, and quantifies business impact. By aligning AI-driven intelligence with human judgment, organizations move from reactive firefighting to proactive value optimization."With Unison Decision-Centric Planning, we help customers move beyond reactive firefighting," said Tom Wouters, Chief Product Officer at OMP."By combining human expertise with advanced AI and scenario modeling, we enable confident, proactive decisions that drive agility, resilience, and measurable business impact."Human-AI synergy for smarter, faster decisionsUnison Decision-Centric Planning leverages UnisonIQ to orchestrate AI agents, generative AI assistants, and advanced optimization engines. Routine manual tasks are automated, freeing planners to focus on cross-functional collaboration and decision-making. Explainable AI ensures transparency and trust, while autonomous agents continuously monitor supply chain signals and act in real time.Proven impact at Evonik OxenoEvonik Oxeno, a leading producer of C4 chemicals, partnered with OMP to transition from reactive planning to always-on, scenario-based decision-making. By leveraging real-time insights and simulations through Unison Planning, planners can anticipate disruptions and respond faster, improving agility and overall business performance."Unison Decision-Centric Planning has reinforced trust in the system among planners and executives. Scenario-based decision-making enables us to respond faster and improve company performance," said David Kochanek, Supply Chain Solution Manager at Evonik Oxeno."Scenario-based decision-making enables us to respond faster and improve company performance."Always-on decision intelligence at scaleUnison Decision-Centric Planning introduces event-driven agents that continuously assess opportunities or risks, aligning decisions with strategic and financial objectives. By running hundreds of scenarios, organizations can anticipate disruption, optimize outcomes, and achieve measurable gains in service levels, cost efficiency, sustainability, and decision velocity."Organizations can run hundreds of scenarios to prepare for disruptions and optimize outcomes."Learn more about decision-centric planningDiscover how decision-centric planning can transform your supply chain. Explore OMP's resources, including the always-on e-book and the full Evonik Oxeno success story. Learn more.About OMPOMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, packaging, plastics - benefit from using OMP's unique Unison Planning™.Solution and product inquiriesContact OMPMedia inquiriesKira Perdue (Carabiner)SOURCE: OMP Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 3, 2026 - (ACN Newswire via SeaPRwire.com) – MMG Limited (“MMG”, stock code: 1208) has today announced its 2025 Annual Results, delivering record revenue and profit. The exceptional result reflects disciplined operational and financial management, supported by favourable commodity prices.Watch the Message from CEO:https://drive.google.com/file/d/17KFqXpd_2sjdZDKfBBMBv1ee09Zic-e6/view'usp=drive_linkSafety is MMG’s first value and the Company recorded a Total Recordable Injury Frequency (TRIF) of 2.06 per million hours worked for the full year 2025. The Significant Events with Energy Exchange Frequency (SEEEF) was 0.80 per million hours worked, up slightly from 0.78 per million hours worked in 2024.Total earnings reached record highs. EBITDA rose to US$3,412.1 million, while EBIT increased to US$1,999.1 million. MMG also generated record net operating cash flow of US$2,689.5 million and free cash flow of US$1,608.1 million. Net profit after tax increased to US$955.2 million (US$509.4 million attributable to equity holders), up from US$366.0 million (US$161.9 million attributable to equity holders) in 2024.“We ended the year strongly, delivering an excellent finish in terms of our operational and financial performance,” said MMG’s CEO Ivo Zhao. “This included Las Bambas achieving their second-highest annual copper production, up 27 per cent from 2024, with records set for annual ore mined, ore milled and overall recovery rates.”MMG’s balance sheet is now substantially stronger, with reduced net debt and a gearing ratio at a record low of 33 per cent. This included the Las Bambas joint venture (JV) dividend payment, which facilitated the early repayment of US$500 million in Khoemacau borrowings. The remaining funds were used to repay other debts, deleverage the company’s balance sheet and support the early stages of Khoemacau's expansion.MMG’s total copper production rose 27 per cent year-on-year to 506,899 tonnes, driven by technology, innovation and stable operation across both pits at Las Bambas. Las Bambas contributed US$4,447.0 million in revenue (49 per cent year-on-year growth), contributing the largest share of the Group’s revenue growth. Total zinc production increased by six per cent to 232,060 tonnes, underpinned by a record year at Dugald River. Precious metals production at Rosebery also performed well.“While we remain mindful of the dynamic market environment, we are focused on delivering our growth plans and harnessing emerging technologies to drive long-term value for shareholders,” said Mr Zhao. “An important contribution to MMG’s growth pipeline is our Khoemacau Expansion project. Our plan is to increase annual production capacity to 130,000 tonnes of copper in copper concentrate by 2028, with the potential for 200,000 tonnes over time.”During 2025, the Company’s market capitalization exceeded HK$100 billion, including strong demand for its first convertible bond.MMG’s 2025 Annual Results Report is available here.Las BambasKhoemacauDugald RiverRoseberyKinseverePhoto download link: https://drive.google.com/drive/folders/1o9ArIgbJSAT2z1UCt8ttB69L9l9jiebx'usp=drive_linkAbout MMGFounded in 2009, MMG’s vision is to create a leading international mining company for a low carbon future. The company is headquartered in Melbourne, Australia and Hong Kong and Beijing, China and listed on the Hong Kong Stock Exchange (HKEX1208).MMG’s portfolio supports copper, zinc and cobalt production, with soon to be nickel – products that are critical to achieving global decarbonisation and electrification targets. With operations in Australia, Botswana, the Democratic Republic of Congo and Latin America, the company makes a direct contribution to the economic and social development of its host countries.In 2025, MMG released its first nature strategy and progressed a refresh of its climate strategy. MMG's membership of the UN Global Compact further aligns the company with global leaders on human rights, climate action, and governance. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 3, 2026 - (ACN Newswire via SeaPRwire.com) – On 02 March 2026, Concord New Energy Group (“CNE Group”) signed a Memorandum of Understanding (MOU) in Singapore with Bridge Data Centres (BDC), a portfolio company of Bain Capital.Under the MOU, the parties will jointly explore diversified energy supply pathways integrating renewable energy and hydrogen solutions on a global basis to support the low-carbon transformation of data centre infrastructure. The collaboration includes the development of Singapore’s first barge-based hydrogen power generation solution designed specifically for artificial intelligence (AI) digital infrastructure.The partnership will encompass hydrogen power pathway studies, system integration design, energy storage deployment assessments, and optimization of power procurement mechanisms. Through these initiatives, both parties aim to enhance energy reliability, operational flexibility, and long-term sustainability for next-generation data centre campuses.CNE brings extensive expertise in renewable energy development and integrated energy systems, while BDC contributes leading operational capabilities in digital infrastructure. The collaboration is expected to accelerate the convergence of clean energy solutions and advanced computing infrastructure.As artificial intelligence and high-performance computing continue to reshape regional economies, this partnership will further support Singapore’s ambition to remain a leading digital hub powered by low-carbon energy.Bridge Data Centres (BDC)Headquartered in Singapore, Bridge Data Centres (BDC) is a leading hyperscale data centre platform in the Asia Pacific region backed by Bain Capital. The company focuses on the development and operation of high-performance digital infrastructure across multiple high-growth markets. BDC is committed to delivering resilient, reliable, and sustainable infrastructure solutions to support the rapid growth of cloud computing and artificial intelligence (AI) applications.Concord New Energy Group (CNE)Headquartered in Singapore, Concord New Energy Group is a renewable energy developer and operator listed on the Main Board of the Hong Kong Stock Exchange and the Singapore Exchange. With 20 years of experience in the renewable energy industry, CNE’s portfolio covers wind power, photovoltaic (PV) and energy storage projects. The Group has strong capabilities in project development, investment, construction and long-term asset management, and currently holds over 5GW of equity capacity globally. CNE remains committed to promoting the application of clean energy and providing integrated energy solutions to support sustainable development. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- First glucokinase-activator (GKA) approval outside mainland China- Approval supports a differentiated approach to Type 2 diabetes (T2D) management- Hong Kong will serve as Hua Medicine’s launchpad for international market expansionSHANGHAI, HONG KONG, Mar 3, 2026 - (ACN Newswire via SeaPRwire.com) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS(R)) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.Under Hong Kong's "1+" pharmaceutical regulatory innovation mechanism, the approval follows the acceptance of dorzagliatin’s New Drug Application (NDA) by the Hong Kong Department of Health in September 2025. As the first innovative drug for chronic metabolic diseases approved for marketing since the launch of "1+" mechanism, the successful rollout of dorzagliatin not only brings an entirely new treatment option for patients with Type 2 diabetes in Hong Kong, but also marks a crucial step in Hua Medicine's strategic layout to expand from China to the Southeast Asian and global markets with Hong Kong as its hub.Cao Beili, Vice President of Department of Corporate Operation and Great Bay Development of Hua Medicine, stated: “Among the three new drugs approved under the ‘1+’ mechanism, MYHOMSIS(R) is an innovative medicine developed in China that has obtained approval from the National Medical Products Administration (NMPA). It is also the first primary care drug product approved under the ‘1+’ mechanism.”Dr. Chen Li, Founder, Executive Director and CEO of Hua Medicine, stated: "The approval of dorzagliatin for marketing in Hong Kong is a significant milestone in the Company's development. As one of the first original innovative drugs to benefit from Hong Kong's '1+' mechanism, this achievement not only reflects Hong Kong's support for innovative drugs, but also validates the global competitiveness of China's independently developed innovative drugs. The launch in Hong Kong is a key step for Hua Medicine to enter the Southeast Asian and international markets. We will take Hong Kong as the hub to build a marketing network and R&D cooperation system radiating Southeast Asia and connecting the world, bringing China's independently developed innovative drugs to more diabetes patients in countries and regions around the globe. Meanwhile, we will continue to advance the marketing approval process of dorzagliatin in the Macao Special Administrative Region of China to achieve its full rollout in the Guangdong-Hong Kong-Macao Greater Bay Area, and relying on the regional advantages in mechanisms, talent and medical resources, we will advance the clinical expansion of new indications and the international promotion of MYHOMSIS(R)."Global First-in-Class & Local Clinical Data: Establishing a New Model for Restoring Glycemic Homeostasis in Diabetes TreatmentType 2 diabetes remains a progressive disease characterized by impaired glucose regulation and declining pancreatic β-cell function over time. While many therapies address downstream consequences of dysregulated blood glucose, dorzagliatin is a global first-in-class GKA innovative drug independently developed by Hua Medicine. Its core innovation lies in repairing the impaired function and expression of glucokinase (GK) in patients with Type 2 diabetes, thereby improving patients' glucose sensitivity from the source and ameliorating the imbalance of glycemic homeostasis. The drug acts on multiple key organs of glucose metabolism including the islets, intestines and liver, exerting a synergistic effect through multiple targets:- enhancing glucose-stimulated insulin secretion from pancreatic β-cells, - promoting GLP-1 release from intestinal L-cells, and - modulating hepatic glucose output through glycogen regulation.This coordinated, multi-organ profile differentiates dorzagliatin from existing oral antidiabetic therapies and reflects Hua Medicine’s focus on addressing glucose homeostasis dysregulation and controlling the progression of Type 2 diabetes and the occurrence of its complications from the source.Dorzagliatin was approved for marketing by the China National Medical Products Administration (NMPA) in September 2022 for two indications, both to improve blood glucose control for T2D patients:1) It can be used as mono-therapy treatment for drug-naïve T2D patients, as first-line treatment,2) When metformin hydrochloride alone exhibits poor blood glucose control in T2D patients, it can be used in combination with metformin hydrochloride.Since January 1, 2024, dorzagliatin is included in China’s National Reimbursement Drug List and has been prescribed to over 200,000+ patients in mainland China already. In June last year, the interim analysis of real-world research presented at the Scientific Sessions of the American Diabetes Association (ADA) further verified its efficacy and safety in a broad population.Leveraging Hong Kong's "1+" Mechanism to Accelerate Access to Innovative Drugs for Hong Kong ResidentsThe formulation and implementation of Hong Kong's "1+" pharmaceutical regulatory innovation mechanism is an important measure taken by the Hong Kong SAR Government to enhance the accessibility of medical innovation and attract high-quality global innovative drugs to launch in Hong Kong. This mechanism allows innovative drugs already approved in designated major markets (such as China, the United States, Europe, etc.) to secure marketing approval in Hong Kong through a simplified application pathway and data mutual recognition mechanism, which greatly shortens the time cycle from R&D to clinical access of innovative drugs for Hong Kong patients, while ensuring the safety and efficacy of the drugs.With its local clinical data, clear therapeutic value and good safety record in China, dorzagliatin has become one of the first original Chinese innovative drugs to be rapidly approved through Hong Kong's "1+" mechanism. This approval is an important practical achievement of the mechanism in enabling the launch of global innovative drugs in Hong Kong, which not only reflects the high recognition of the clinical value of dorzagliatin by the Department of Health of Hong Kong, but also highlights the core role of the "1+" mechanism in connecting the Chinese market and international pharmaceutical markets and accelerating the flow of innovative medical resources.Building on Hong Kong's Experience to Empower Global Diabetes ManagementDiabetes is a major challenge for global public health. According to the 2025 Global Diabetes Map released by the International Diabetes Federation (IDF), the number of adults aged 20-79 with diabetes worldwide reached 589 million in 2024, and this figure is projected to rise to 853 million by 2050. In Hong Kong, China, diabetes is also a prominent public health issue. According to the Population Health Survey 2020-2022 conducted by the Department of Health of Hong Kong, 6.9% of people aged 15 or above reported having been diagnosed with diabetes by a doctor, and an additional 1.8% had hyperglycemia without being diagnosed with diabetes. In 2022, more than 600 death registrations in Hong Kong were attributed to diabetes, ranking 11th among the leading causes of death.[1]Hong Kong has accumulated rich experience in diabetes management, forming a comprehensive system covering disease surveillance, prevention, screening, treatment and community management, and its community-based public-private partnership model for diabetes management has achieved remarkable results. Following its launch in Hong Kong, dorzagliatin is expected to be deeply integrated with the local mature diabetes management system, and help improve patients' quality of life, control disease progression and reduce medical burdens through personalized treatment plans.At present, Hua Medicine is collaborating with the research team led by Professor Juliana Chan, a world-renowned endocrinologist from the Chinese University of Hong Kong, to conduct the SENSITIZE series of studies to further explore the mechanism by which dorzagliatin improves pancreatic β-cell glucose sensitivity. The published results of the SENSITIZE 1/2 studies have shown that dorzagliatin can significantly improve the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and enhance basal insulin secretion in patients with newly diagnosed type 2 diabetes. In addition, dorzagliatin can also significantly improve the second-phase insulin secretion and β-cell glucose sensitivity in populations with impaired glucose tolerance (IGT).Hua Medicine will continue to deepen cooperation with top local research institutions and clinicians to further explore the potential of dorzagliatin in pre-diabetes intervention, early treatment and complication prevention, accumulate additional international clinical data, lay a solid foundation for the expansion of its indications and global market promotion, and establish personalized intervention and treatment management plans for patients with pre-diabetes and Type 2 diabetes.As a core hub of the Asian pharmaceutical market, Hong Kong, with its unique geographical location, advanced medical infrastructure, international business environment and close linkage with the Southeast Asian market, is expected to become the strategic starting point for Hua Medicine to expand into Southeast Asia and the global market. Relying on Hong Kong's advantage of pharmaceutical regulatory standards aligned with international norms and leveraging its financial and capital market strengths, Hua Medicine will further advance the registration and application of dorzagliatin in the Southeast Asian market to quickly cover the large population of diabetes patients in the region. Meanwhile, the Company will deepen cooperation with partners in the global pharmaceutical industry chain to accelerate the international commercialization of dorzagliatin.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS(R)) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail:pr@huamedicine.com[1] https://www.chp.gov.hk/sc/features/37474.html Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com